Comments
The Dr Reddy’s Laboratories scrip gained 4.52 per cent on the BSE on Thursday to end at ₹3,094.95. The board of directors of the Hyderabad-based company had on Wednesday approved a proposal to buy back equity shares of the company for an aggregate amount not exceeding ₹1,569 crore at a price not exceeding ₹3,500 a share. The buyback is proposed on account of the company’s strong cash flow position and is expected to be EPS accretive contributing to an overall enhancement of value for shareholders going forward. Our Bureau
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.